BioMedNewsBreaks – Odyssey Health Inc. (ODYY) Completes Safety Evaluation of Cohort II for Novel Drug to Treat Concussion

Odyssey Health (OTC: ODYY), f/k/a Odyssey Group International Inc., a company focused on developing unique, life-saving medical products, today announced positive safety findings from cohort II of its phase I clinical trial. According to the update, the trial involves administering PRV-002, Odyssey’s novel drug to treat concussion, to healthy human subjects. Cohort II data indicates that the drug was safe and well-tolerated. “PRV-002 continues to be well-tolerated as we increase the intranasal dose levels,” said Michael Redmond, CEO of Odyssey Health. “We look forward to completing phase I clinical trials and moving into a phase II/III to determine the efficacy of PRV-002 for concussed patients. I believe that intranasal brain-targeting will be the key to its success. We are currently in discussions with military training sites for our phase II/III clinical trials.”

To view the full press release, visit https://ibn.fm/4i40l

About Odyssey Health Inc. (formerly Odyssey Group International Inc.)

Odyssey is a medical company with a focus in the area of life-saving medical solutions. Odyssey’s corporate mission is to create, acquire and develop distinct assets, intellectual property and exceptional technologies that provide meaningful medical solutions. The company is focused on areas that have an identified technological advantage, provide superior clinical utility, and have a substantial market opportunity.

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.